Response Genetics' Q2 Revenues Nearly Triple | GenomeWeb

NEW YORK (GenomeWeb News) – Response Genetics today reported that its second-quarter revenues nearly tripled, due to sales of the firm's ResponseDx genetic tests.

The Los Angeles-based firm reported total revenues of $5.6 million for the three-month period ended June 30, compared to $1.9 million for the second quarter of 2009. It said that sales of its ResponseDx tests increased 687 percent to $3.5 million for the quarter from $446,000 for Q2 2009.

Response Genetics also trimmed its net loss to $425,038, or $.02 per share, from $2.4 million, or $.19 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.